COMMUNIQUÉS West-GlobeNewswire

Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
24/08/2026
Positive topline results from Phase 3 trial of personalized cancer vaccine for melanoma de-risk LNP-mRNA therapies such as CancerVax Lehi, Utah, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc. , the developer of a [...]
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
24/08/2026
CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to [...]
Belite Bio to Host Virtual Commercial Day on September 2, 2026
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Lakefront Receives Transparency Notification from Bank of America
24/08/2026
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian [...]
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
24/08/2026
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug [...]
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
24/08/2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a [...]
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
24/08/2026
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Longeveron Announces 1-for-10 Reverse Stock Split
24/08/2026
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, [...]
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
24/08/2026
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Zealand Pharma – Notification of holding of treasury shares
24/08/2026
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 34 - 2026
24/08/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 17 au 21 août 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026
24/08/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 17 th to 21 st August 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Ozari Health Offers Compounded Semaglutide From $86 Per Month and Tirzepatide From $125 Per Month on Nationwide Telehealth Platform as Updated 2026 GLP-1 Pricing Data Goes Live
24/08/2026
LegitScript-certified platform connects patients with licensed providers for GLP-1 weight management, with all-in pricing, no membership fees, and no long-term contracts, and publishes an open dataset comparing real [...]
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
24/08/2026
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional [...]
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
24/08/2026
- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP- [...]
ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast [...]
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on [...]
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
24/08/2026
Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ( [...]
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
24/08/2026
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, [...]

Pages